tradingkey.logo
tradingkey.logo

Merck & Co Inc Says Winrevair Meets Primary Endpoint In Phase 2 Cadence Trial

ReutersMar 29, 2026 3:49 PM

- Merck & Co Inc MRK.N:

  • POSITIVE DATA FROM PHASE 2 CADENCE TRIAL PROVIDES DEFINITIVE PROOF-OF-CONCEPT FOR WINREVAIR™ (SOTATERCEPT-CSRK) IN ADULTS WITH THE SYNDROME OF COMBINED POST- AND PRECAPILLARY PULMONARY HYPERTENSION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION

  • MERCK & CO INC - WINREVAIR MEETS PRIMARY ENDPOINT IN PHASE 2 CADENCE TRIAL

  • MERCK & CO: TOTALITY OF EVIDENCE ACROSS HEMODYNAMIC, FUNCTIONAL, ECHOCARDIOGRAPHIC AND CLINICAL ENDPOINTS SUPPORTS ADVANCING DEVELOPMENT OF WINREVAIR

  • MERCK & CO INC - WINREVAIR TO ADVANCE INTO REGISTRATIONAL PHASE 3 PROGRAM IN CPCPH-HFPEF

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI